Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Gains from Sales and Divestitures (2020 - 2025)

Kymera Therapeutics (KYMR) has disclosed Gains from Sales and Divestitures for 6 consecutive years, with $284026.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures rose 62.8% to $284026.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $284026.0, a 62.8% increase, with the full-year FY2025 number at $284026.0, up 62.8% from a year prior.
  • Gains from Sales and Divestitures was $284026.0 for Q4 2025 at Kymera Therapeutics, up from $278130.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $284026.0 in Q4 2025 to a low of $14215.0 in Q1 2022.
  • A 5-year average of $98640.0 and a median of $47123.5 in 2021 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: crashed 56.56% in 2022, then skyrocketed 371.47% in 2024.
  • Kymera Therapeutics' Gains from Sales and Divestitures stood at $84859.0 in 2021, then crashed by 56.56% to $36866.0 in 2022, then rose by 7.17% to $39511.0 in 2023, then surged by 341.56% to $174463.0 in 2024, then soared by 62.8% to $284026.0 in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Gains from Sales and Divestitures are $284026.0 (Q4 2025), $278130.0 (Q3 2025), and $224882.0 (Q2 2025).